Navigation Links
MIV Therapeutics Announces Renowned Researcher to Detail Milestone,Pre-Clinical Results at Prominent International Conference EuroPCR,2007

ATLANTA--(BUSINESS WIRE)--May 22, 2007 - MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for Cardiovascular stents and other implantable medical devices, is pleased to announce that results from an animal trial comparing its proprietary polymer free Hydroxyapatite-coated drug-eluting cardiovascular stent to J&J's Cypher Stent will be presented at this weeks EuroPCR 2007 conference in Barcelona, Spain.

Dr Willem J. van der Giesen, MD, PhD from the Erasmus University Medical Center will make a presentation on next generation drug eluting stents, in which he will discuss the results of the 4 week porcine study, performed by the Department of Cardiology, Thoraxcenter, Erasmus University Medical Center in the Netherlands, an independent research organization.

The study indicated that three variations of MIVT's Hydroxyapatite-based Drug-Eluting stents were at least as effective as, and in some cases, better than one of the worlds leading drug-eluting cardiovascular stents produced by Johnson & Johnson (Cypher(TM)). These results provided the necessary data to advance the technology to human studies.

Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT's HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances.

HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. Some of the most recent information presented at various conferences estimated that thrombogenicity was identified in at least 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2
... as Marker of,Treatment Success -, SAN FRANCISCO, ... presented at the 59th Annual Meeting of,the American ... shows that,PEGASYS(R) (peginterferon alfa-2a) treatment regimens result in ... patients as,compared to regimens with another pegylated interferon.(1), ...
... Denmark, October 31 , - DoctorConsult in ... Improve Clinician Decision Making and Health Care Business,Performance, ... and more than a,century of experience as a ... provide interactive clinical reference and clinical decision,support (CDS) ...
Cached Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
(Date:2/27/2015)... Wisconsin (PRWEB) February 27, 2015 Dr. ... plastic surgeons , is pleased to announce the expansion ... now open in Delafield. Quintessa has begun seeing patients ... the new Delafield location will offer a variety of ... including: Botox, filler injectables, micro laser peels, chemical peels, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 On February 24 ... Real Liquid Botox ,” that details the development of ... is working its way through FDA trials. For those afraid ... cream is very attractive. Of course, if the drug ultimately ... at a physician’s office. (see: goo.gl/PQvQwk) , “As the article ...
(Date:2/27/2015)... Beach, FL (PRWEB) February 27, 2015 ... medical companies, devices and pharmaceuticals, Benedict Advertising & ... as its newest client. The company’s patented NITROUSEAL® ... a pain-free, no-stress method of sedation. , Sedation ... medical patient comfort to a new level, though ...
(Date:2/27/2015)... February 27, 2015 The winter season is ... and expansion. When mold grows, it can be harmful to ... to avoid the consequences of mold growth with the help ... is offering tips on the best ways to prevent mold ... which makes perfect conditions for mold to thrive. Mold must ...
(Date:2/27/2015)... 2015 Victorian Hotel recently celebrated Valentine’s ... who wanted to spend the auspicious day together. This ... a jump on Valentine’s Day with a sweet overnight ... of their luxurious rooms. , The hotel started ... for a mouthwatering 3 course meal at Café 335. ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Is Topical Botox the Next Big Thing? 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2
... of asthma-causing immune molecules Asthma and ... Soluble IgE molecules, produced by immune cells known as ... Therapeutic targeting of IgE in the blood can neutralize ... allergic asthma. However, this approach does not halt IgE ...
... was worse than physical abuse alone, study found , MONDAY, ... finds that older women who are exposed to physical and ... twist did show up in the results, study author Dr. ... more damaging than physical abuse alone. , Why? "The physical ...
... be wise, expert says, , MONDAY, May 10 (HealthDay ... its authors describe as a precise description of the ... heart-related fats. , It provides "the best evidence yet ... blood lipids profile," said Dr. Joan Sabate, who chairs ...
... ... Beard & Arsenault in Louisiana says the estimated 5,000 U.S. deaths each year from ... the most part preventable.” , ... Alexandria, LA (PRWEB) May 10, 2010 – Louisiana’s Department of Health and ...
... - The Massachusetts Eye and Ear Infirmary, Harvard Medical ... renewal from the National Institutes of Health, National Eye ... scientists to promote translational and clinical research into cures ... five-year K12 grant to Mass. Eye and Ear (representing ...
... ... ... E. Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical ... Lipscomb University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn ...
Cached Medicine News:Health News:JCI online early table of contents: May 17, 2010 2Health News:JCI online early table of contents: May 17, 2010 3Health News:JCI online early table of contents: May 17, 2010 4Health News:JCI online early table of contents: May 17, 2010 5Health News:JCI online early table of contents: May 17, 2010 6Health News:JCI online early table of contents: May 17, 2010 7Health News:JCI online early table of contents: May 17, 2010 8Health News:Older, Abused Women Suffer Poor Mental Health 2Health News:Eating Nuts May Help Cholesterol Levels 2Health News:Eating Nuts May Help Cholesterol Levels 3Health News:Food Poisoning Suspected in 3 Deaths, 40 Illnesses at Central State Hospital in Pineville, LA 2Health News:Mass. Eye and Ear receives NEI grant renewal for 'growing' clinical/scientists 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Classic proven design with superior clinical results...
... Using high-performance materials contributes to ... addition to surgical procedures and technique, ... great bearing on your patients' outcomes, ... DePuy developed MARATHON Cross-Linked Polyethylene. MARATHON ...
Medicine Products: